Tarsus Pharmaceuticals Stock Today
| TARS Stock | USD 46.40 0.18 0.39% |
Performance21 of 100
| Odds Of DistressLess than 16
|
Tarsus Pharmaceuticals is selling for under 46.40 as of the 21st of November 2024; that is 0.39 percent decrease since the beginning of the trading day. The stock's lowest day price was 45.73. Tarsus Pharmaceuticals has less than a 16 % chance of experiencing some financial distress in the next two years of operation and had a solid performance during the last 90 days. Equity ratings for Tarsus Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 2nd of December 2022 and ending today, the 21st of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 16th of October 2020 | Category Healthcare | Classification Health Care |
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. The company has 38.23 M outstanding shares of which 8.16 M shares are at this time shorted by private and institutional investors with about 11.42 trading days to cover. More on Tarsus Pharmaceuticals
Moving against Tarsus Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Tarsus Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Thematic Idea | Biotech (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Biotech, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsTarsus Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Tarsus Pharmaceuticals' financial leverage. It provides some insight into what part of Tarsus Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Tarsus Pharmaceuticals (TARS) is traded on NASDAQ Exchange in USA. It is located in 15440 Laguna Canyon Road, Irvine, CA, United States, 92618 and employs 244 people. Tarsus Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.78 B. Tarsus Pharmaceuticals conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 38.23 M outstanding shares of which 8.16 M shares are at this time shorted by private and institutional investors with about 11.42 trading days to cover.
Tarsus Pharmaceuticals currently holds about 245.36 M in cash with (117.49 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.2.
Check Tarsus Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationThe majority of Tarsus Pharmaceuticals outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Tarsus Pharmaceuticals to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Tarsus Pharmaceuticals. Please pay attention to any change in the institutional holdings of Tarsus Pharmaceuticals as this could imply that something significant has changed or is about to change at the company.
Check Tarsus Ownership Details
Tarsus Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Exoduspoint Capital Management, Lp | 2024-09-30 | 883 K | |
| Ikarian Capital, Llc | 2024-06-30 | 800.3 K | |
| Geode Capital Management, Llc | 2024-06-30 | 773.2 K | |
| Artisan Partners Limited Partnership | 2024-06-30 | 627.6 K | |
| Ensign Peak Advisors Inc | 2024-06-30 | 594.3 K | |
| Polygon Management Ltd | 2024-06-30 | 500 K | |
| Cormorant Asset Management, Llc | 2024-06-30 | 500 K | |
| Lord, Abbett & Co Llc | 2024-06-30 | 463.2 K | |
| Macquarie Group Ltd | 2024-06-30 | 455 K | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 3.8 M | |
| Rtw Investments, Llc | 2024-06-30 | 3.4 M |
Tarsus Pharmaceuticals Historical Income Statement
Tarsus Stock Against Markets
Tarsus Pharmaceuticals Corporate Management
| Leonard JD | Chief Officer | Profile | |
| Scott Youmans | Vice Sales | Profile | |
| Seshadri Neervannan | Chief Officer | Profile | |
| Adrienne Kemp | Senior Communications | Profile | |
| Elizabeth MD | Chief Director | Profile | |
| Aziz MBA | Chief Officer | Profile |
Additional Tools for Tarsus Stock Analysis
When running Tarsus Pharmaceuticals' price analysis, check to measure Tarsus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tarsus Pharmaceuticals is operating at the current time. Most of Tarsus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tarsus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tarsus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tarsus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.